Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
Paul Harmatz(Royal Manchester Children's Hospital), Celeste Decker(BioMarin (United States)), Ida Vanessa Döederlein Schwartz(Statistics Collaborative), Maurizio Scarpa(University of Udine), David Ketteridge(Women's and Children's Hospital), Robert D. Steiner(Oregon Health & Science University), Nathalie Guffon(Hôpital Edouard Herriot), Elisa Leão Teles(Hospital de São João), Barbara Plecko(Graz University Hospital), Laila Arash(University of Padua), Roberto Giugliani(Instituto de Biologia Molecular e Celular), Clara Sá-Miranda(Hôpital Edouard Herriot), Michael Beck(Universitätskinderklinik), John J. Hopwood(Women's and Children's Hospital), Stuart J. Swiedler(Hospital de São João), J. E. Wraith(Boston Children's Hospital), Zi-Fan Yu(Statistics Collaborative), Chester B. Whitley(University of Minnesota Medical Center), Paige Kaplan(Children's Hospital of Philadelphia)
Cited by 216
Related Papers
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene
|Nature Genetics|1999|571
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364